Conference Reports for NATAP

Back

DDW - Digestive Disease Week 2014 May 4, 2014, Chicago Illinois, United States     VA Patients Are Good Candidates for Early HCV Treatment - (08/13/14)   Projected Health and Economic Impact of Hepatitis C on the United States Veterans Administration Health System From 2014 To 2024 - (05/13/14)   Intake of Coffee and Caffeine are Associated with Decreased Risk of Hepatitis C-related Hepatic Fibrosis - (05/09/14)   The Tip of an Iceberg - Who Is Known to Have Hepatitis C? - 'majority remain undiagnosed, especially in younger men outside the birth cohort....birth-cohort & risk based screening needed.....30-49 age.....88-65% remain undiagnosed....less than 33% overall were diagnosed with HCV.....prevalence 1-3.3%' - (05/08/14)   Bridging the Gap between HCV Screening and Access to Care: Insights from National Health and Nutrition HCV Follow-up Study, 2001-2010 - (05/08/14)   Comorbid Conditions Associated with Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization - (05/07/14)   PEARL-II: RANDOMIZED PHASE 3 TRIAL OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333 WITH OR WITHOUT RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 1B-INFECTED, TREATMENT-EXPERIENCED PATIENTS - (05/07/14)   Comorbid Conditions Associated with Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization - (05/06/14)   Quality of Life, Productivity, and Activity Impairment Among US Survey Respondents With Hepatitis C: An Evaluation of HCV and Six Select Medical Conditions - (05/06/14)   All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and BMS-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection - (05/06/14)   Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - (05/05/14)   Low treatment rates and suboptimal treatment completion rates to HCV therapy: A real world analysis of a large US cohort - (05/05/14)   Treatment Satisfaction in Clinical Trial (AVIATOR) Patients Treated with Interferonfree, Oral DAA Regimens: External Validation of the Hepatitis C Virus (HCV) Treatment Satisfaction (HCVTSat) Instrument - (05/05/14)   PEARL-IV: A 12-week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves SVR12 Rates ≥90% in Treatment-naïve Adults Infected With Hepatitis C Virus Genotype 1a - (05/05/14)